New Step by Step Map For zofran and phenobarbital
New Step by Step Map For zofran and phenobarbital
Blog Article
Monitor Closely (1)viloxazine will boost the level or effect of phenobarbital by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
フェニトインやカルバマゼピン、バルプロ酸など他の抗てんかん薬と同様に葉酸の吸収や代謝に影響し、貧血（巨赤芽球性貧血）を引き起こしうる。
أسئلة وإجابات طبية أطباء متخصصين للإجابة على استفسارك
Narcotics, hypnotics or sedatives can make additive neuropsychiatric side effects. Steer clear of use and monitor patients obtaining the combination for effects of excessive CNS toxicity.
テキストはクリエイティブ・コモンズ 表示-継承ライセンスのもとで利用できます。追加の条件が適用される場合があります。詳細については利用規約を参照してください。
Monitor Carefully (1)phenobarbital will lower the level or effect of omeprazole by influencing hepatic enzyme CYP2C19 metabolism.
Consulting with a holistic veterinarian might help make certain that you’re using the proper dosage and potency for optimal efficacy for a particular condition. If the dosage is too reduced, it is probably not effective.
Although normally Safe and sound and effective when prescribed by a veterinarian, phenobarbital may cause side effects in some animals.
By clicking send out, you admit that you've got permission to email read more the recipient with this information and facts.
Monitor Intently (one)phenobarbital will minimize the level or effect of levamlodipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
No dosage adjustment for ondansetron is recommended for patients on these drugs.Insignificant (1)phenobarbital will minimize the level or effect of ondansetron by affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown.
sage decreases effects of phenobarbital by pharmacodynamic antagonism. Minimal/Significance Unidentified. Theoretical interaction; some species of sage might cause convulsions.
Comment: Barbiturates may perhaps boost adverse effects, together with respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates maximize metabolism and decrease blood concentrations of TCAs.
On initiation or discontinuation of dupilumab in patients who're acquiring concomitant CYP450 substrates, specially those with a narrow therapeutic index, consider monitoring for therapeutic effect.